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Foreword 
There are nine different equid herpesviruses (EHVs). Five types (EHV-1 to EHV-5) infect the domestic horse, while 
EHV-6 to EHV-9 are associated with infections in wild equids including asses and zebra. This review focuses on 
the commonest and most important clinical pathogens, the alphaherpesviruses EHV-1 and 4. These are respiratory 
pathogens and are also responsible for abortion and neurological disease. Several aspects of the biology of these vi-
ruses makes their control challenging. In particular, latent infection and reactivation of infection under stress, with 
subsequent virus shedding, makes elimination of these viruses impossible. Biosecurity measures are important both 
for minimising the risk of an outbreak and for controlling any outbreak when it occurs. Recognition of the disease and 
confirmatory diagnosis are also important in order for appropriate biosecurity measures to be instigated. Vaccination 
in key demographic groups is also important to reduce severe clinical disease. Unfortunately many horse owners are 
unaware of EHV or the importance of biosecurity measures and vaccination for control. 
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Equine herpesviruses:
a roundtable discussion
T here are nine different equid her-pesviruses (EHVs). Five types (EHV-1 to EHV-5) infect the domestic horse, while EHV-6 
to EHV-9 are associated with infections in 
wild equids, including asses and zebra. The 
alphaherpesviruses EHV-1 and EHV-4 are 
respiratory pathogens and are also responsible 
for abortion and neurological disease. EHV-3 
is a venereal pathogen causing coital exan-
thema and will not be discussed in this article. 
The gammaherpesviruses EHV-2 and EHV-5 
have been associated with ocular and respira-
tory disease, but their significance has not been 
fully determined and discussion is beyond the 
scope of this article. This review focuses on the 
commonest and most important clinical path-
ogens, EHV-1 and EHV-4, and outlines their 
biology; this will demonstrate the challenges of 
control and the importance of vaccination in 
key demographic groups.
A recent online survey of more than 1000 
horse owners identified a striking lack of 
awareness of the risks of EHV to their horse, 
and of the importance of biosecurity measures, 
in combination with vaccination, to prevent 
and control the disease (Data on File, Equine 
Herpes Virus Horse Owner Survey March 
2019, Zoetis Inc). Encouragingly, a majority 
stated they would vaccinate based on veteri-
nary advice.
Prevalence and economic 
importance of EHV-1 and 
EHV-4 in the UK
EHV-1 and 4 are highly host-adapted and suc-
cessful equine pathogens. Antigenically, they 
are closely related and develop cross-reactive 
antibody responses. Their sophisticated life cy-
cle ensures their spread and persistence within 
the global horse population. There is early and 
widespread infection of young stock, which 
combined with widespread latency and reac-
tivation throughout life ensures endemic in-
fection cycles with silent transmission. Spread 
and persistence of the virus is not dependent 
on clinical disease, thus ensuring transmission 
down the generations. (Allen, 2002).
Different disease syndromes
EHV-1 and 4 are infectious respiratory patho-
gens. EHV-1 is associated with four clinical 
disease syndromes (Table 1).
Many factors influence the severity of disease 
following EHV-1 infection, including virulence 
of the virus strain (which varies markedly), 
host immunological status and challenge dose, 
amongst others. Neuropathogenic and non-neu-
ropathogenic virus strains have been described; 
however, both strains can cause equine herpes-
virus myeloencephalopathy (EHM) and the dif-
ferentiation is not useful clinically (Lunn et al, 
2009). EHV-4 is principally a cause of respira-
tory disease, although rare, highly virulent en-
dotheliotropic and thus abortigenic strains exist.
Disease outbreaks occur sporadically and 
the recent UK data is shown in Table 2 (data 
courtesy of Dr F Whitlock, Animal Health 
Trust (AHT), Newmarket). The occurrence of 
disease is likely to under-reported, due to cases 
going undiagnosed. 
Table 1. Disease syndromes caused by EHV-1
Syndrome Clinical signs of disease
Common infectious or 
non-infectious differential 
diagnoses
Respiratory Inapparent or mild but potentially clinically 
significant acute disease in older primed 
animals
More severe disease of longer duration 
in young, immunologically naive animals 
Cough is occasional
Serous nasal discharge or mucopurulent 
discharge if secondary bacterial infection
EHV-4
Equine influenza virus (EIV)
Equine viral arteritis (EVA)
Equine rhinitis virus (ERV)
Streptococcus equi ssp. zooepi-
demicus and equi 
Inflammatory airway disease
Abortion Usually in pregnant mares beyond 5 months 
of gestation (last trimester)
Typically ‘red bag’ presentation
No warning signs
Umbilical cord torsion
Bacterial/fungal placentitis
Stillbirth/dystocia
Leptospirosis
Twinning
Body pregnancy
Neonatal foal 
death
Very weak, ‘ragdoll’, sleepy foal Septicaemia secondary to failure 
of passive transfer
Neonatal isoerythrolysis
Neurological 
disease (equine 
herpesvirus 
myeloencepha-
lopathy (EHM))
Ranges from mild hindlimb ataxia to quad-
raplegia
Cervical verterbral malformation
Cauda equina syndrome
Polyneuritis equi
Trauma
Orthopaedic issues
Table 2. Numbers of confirmed UK outbreaks of disease syndromes 
associated with EHV-1 and EHV-4 infections in 2017 and 2018
Year
Respiratory  
Disease
Abortion EHM
2018 - EHV-1 3 11 2
2018 - EHV-4 14 1 0
2017 - EHV-1 9 7 3
2017 - EHV-4 4 1 0
Data from Animal Health Trust, Newmarket. EHM: equine herpesvirus myeloencephalopathy
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Economic importance 
The direct economic impact of EHV-1 infec-
tion is hard to enumerate,;however, in the large 
Thoroughbred and sports horse breeding cen-
tres around the world, EHV abortion storms are 
economically significant (Allen et al, 1999). For-
tunately, routine vaccination of pregnant mares 
and other horses on studs, modern biosecurity 
systems and improved stud farm management 
have reduced the prevalence of abortion storms. 
However, the threat does not diminish, there-
fore continued implementation of these meas-
ures is vital (McCartan et al, 1995). 
EHM is potential fatal and mortality rates 
can be high (Pusterla and Hussey, 2014). Due 
to the sporadic and unpredictable nature of this 
disease; the potential for most horses to be latent 
carriers; and our lack of understanding of reacti-
vation and/or silent viral transmission, all horses 
remain vulnerable to disease, regardless of their 
economic value. EHM outbreaks have also ne-
cessitated the closure of some equine hospitals, 
with associated economic consequences. Vet-
erinary surgeons and horse-owners alike have a 
responsibility to take every precaution and thus 
keep the prevalence of EHV-related disease as 
low as possible, although it is not possible to re-
duce this to zero risk.
Pathogenesis of EHV infection
EHV-1 typically causes a biphasic pyrexia, how-
ever the pyrexia may only have a single phase 
(Figure 1). Pyrexia may be the only clinical sign 
and is often missed unless routine monitoring 
is undertaken. Abortion occurs any time from 
the second week after infection, and has been 
reported up to 120 days post-infection (Mum-
ford et al, 1987).
Virus rapidly enters respiratory epithelial 
cells and is trafficked through the submucosal 
tissues by direct intracellular transfer to mono-
cytes and lymphocytes. These cells move to lo-
cal blood vessels and respiratory tract lymph 
nodes within 12 hours of infection. Virus am-
plification may occur within the lymph nodes. 
Infected lymphocytes and monocytes enter 
the lymphatics and systemic blood circulation, 
thus establishing a cell-associated viraemia, 
which disseminates infectious virus to sites of 
secondary replication including the endothe-
lium of small blood vessels within the placenta 
and spinal cord; this secondary viral replica-
tion event coincides with the second phase of 
pyrexia. Endothelial cell infection results in a 
vasculitis and thrombus formation. Within the 
placenta or spinal cord this reaction may inter-
rupt the blood supply to these sensitive tissues, 
resulting in ischemia and cell death. The equine 
microcotyledon is very susceptible to thrombus 
formation as it is supplied by a single arteriole 
and venule. The simple epitheliochorial equine 
placenta ‘unzips’, resulting in rapid expulsion 
of the intact fetoplacental unit and the charac-
teristic sudden ‘red-bag’ abortion (Figure 2). 
Damage to the placenta typically results in EHV 
infecting the fetus, hence the virus-positive fetal 
liver, lung and thymus that are often detected 
post mortem. In EHM, compromise of the spi-
nal blood supply results in swelling of neurons 
and haemorrhage, with the extent and location 
of the neurological lesions determining the na-
ture and severity of clinical signs (Table 3). The 
spinal outflow to the caudal and sacral plexus 
is affected most often (Henninger et al, 2007; 
Goehring et al, 2010; Burgess et al, 2012).
Factors that may influence the 
pathogenesis of EHV-1
Factors that affect the severity of clinical signs 
include virulence of the virus strain; infectious 
dose; level of cell-associated viraemia; degree 
of ischaemia and consequent pathology; host 
immunity; and vaccination status (Lunn et 
al 2009). In addition, some strains of EHV-1 
cause immunosuppression in vitro and may 
compromise immune responses in vivo. How-
ever, the importance of this phenomena in vivo 
is unknown (Ma et al, 2013). Recently, genetic 
studies on horses affected by EHM have iden-
tified a single nucleotide polymorphism in a 
platelet-related gene (Brosnahan et al, 2019), 
Table 3. Clinical signs that may develop in association with EHM
Anatomical area Clinical sign Notes
Pelvic limbs Temporary ataxia and paresis 
which may or may not  
progress to quadraplegia
Dragging toes of hind limbs 
when moving on a figure 
of eight
Hindlimb incoordination  
(appears drunk)
Bladder dysfunction Atony with incontinence 
and/or urinary retention
Cutaneous perineum 
and limbs
Sensory defects Caused by sacral nerve 
involvement
Cranial nerve signs Head tilt/facial twitching Rare signs with EHM
Figure 1 . Schematic outlining the approximate timeline of clinical signs, virus shedding and cell-
associated viraemia following experimental infection of ponies on day 0 (courtesy of Dr Julia Kydd).
Pa
ra
m
et
er
Days from experimental infection
0 2 4 6 8 10 12 14 16
Cell-associated viraemia
Nasopharyngeal shedding
Pyrexia
Abortion/ 
paralysis
Pyrexia
Figure 2. Typical ‘red bag’ presentation of the 
abortus in EHV infection. (Image courtesy of 
Prof Ken Smith, RVC)
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which may improve understanding and study of 
why a subset of horses appear susceptible to this 
form of disease. One early report postulated that 
immune complexes between antigen and anti-
body may influence the development of EHM 
(Edington et al, 1986), and although vaccination 
within 5 weeks of exposure has been reported 
as a risk factor, the association between immune 
priming and severity of disease remains specu-
lative (Traub-Dargatz et al, 2013). 
Requirements to prevent and/or 
control EHV-1 infection
Like herpesviruses in other species, control 
of EHV-1 infection is difficult. Currently, 
it is generally agreed that control of EHV-1 
should focus on prevention of infection of 
the respiratory epithelium. However, intracel-
lular translocation is rapid and the window of 
opportunity is short and likely to rely on the 
presence of pre-existing mucosal antibody. Ad-
ditional aims are limiting or even preventing 
the cell-associated viraemia and consequent 
infection of endothelial cells. A continuing 
challenge for researchers is to characterise the 
difference between clinical disease and patho-
genesis following intranasal infection com-
pared with reactivation of latent virus. 
Diagnosis of EHV infection
EHV-1 and EHV-4 infection in a fetus or horse 
may be confirmed by detecting the presence of 
viral DNA and/or infectious virus, character-
istic histopathological changes in fetal tissues, 
or by demonstrating recent exposure of the 
host through the presence of elevated titres of 
anti-EHV-1 or EHV-4 antibodies.
History and clinical signs: EHV-1 infection 
often occurs in the absence of clinically-apparent 
respiratory disease, and even with such signs 
there is little to distinguish EHV-1 respiratory 
disease from other viral and bacterial pathogens. 
Respiratory EHV infection frequently goes unde-
tected. A common misconception is that moni-
toring for respiratory clinical signs provides a 
warning for impending abortion or EHM: most 
horses that abort or develop neurological disease 
after EHV-1 infection do not show signs of res-
piratory disease. If multiple horses are at-risk af-
ter an index case, monitoring rectal temperature 
may help identify potentially infected animals 
that might be at risk of EHM.
Gross pathology of abortion features 
(Figure 3):
zz Rapid expulsion of fetus and placenta intact
zz Fresh fetus
level of the medial canthus should be used (avail-
able from the AHT) to ensure adequate sampling 
of the nasopharyngeal mucosa; short bacteriol-
ogy swabs are not appropriate. Swabs should be 
placed in viral transport medium (e.g. white-top 
tube from AHT). (The sample should be refrig-
erated and time minimised before arriving at the 
laboratory). Tests undertaken may include:
zz Quantitative Polymerase Chain Reaction 
(qPCR) for detecting viral DNA is sensitive 
and allows estimation of the amount of virus 
(‘viral load’) in the sample (Daly and Doyle, 
2003; Hussey et al, 2006;). Turn-around is 
short, with results generally being reported 
on the day of receipt. 
zz Virus Isolation (VI) is traditionally regarded 
as the ‘gold standard’ test but takes 5–7 days 
and is insensitive compared to qPCR. It is 
very useful for research into virus sequences 
and epidemiology to track outbreaks.
Blood
zz qPCR may be used to detect viral DNA in 
buffy coat cells (mainly lymphocytes) from 
blood collected into EDTA. Turn-around is 
short, with results generally being reported 
on the day of receipt.
zz Serology may be used to detect a rise in 
antibody induced by EHV-1 infection and 
thus indicate exposure to EHV-1. In the UK 
complement fixation (CF) test is the default 
serological test.
zz IgM: detectable 4–5 days after infection, 
peaking at 20–30 days, returning to 
zz Meconium staining
zz Blood stained fluid pooling in body cavities
zz Pulmonary oedema
zz Enlarged spotty liver
zz Prominent splenic follicles.
Pathology of EHM features:
zz Vascular thrombosis, infarction and 
inflammation
zz Ischaemic or haemorrhagic degeneration 
(myelopathy).
Sampling to confirm the diagnosis
Case selection is critical: all samples for direct 
demonstration of virus should be collected 
from early clinical cases (ideally <5 days from 
initial fever) whenever possible. This is best 
achieved by identifying in-contact cases with 
pyrexia that may as yet have not shown any 
other clinical signs, although samples from 
clinical cases may also be taken, especially 
if they appear to be the only horses affected. 
Proper selection of cases for sampling is par-
ticularly important in EHM cases, where clini-
cal signs appear towards the end of viraemia 
when viral shedding is waning or may have 
ceased. If fresh fetal tissues are being sent, liais-
ing with the laboratory for weekend and out-
of-hours testing is advised.
Samples
Nasopharyngeal swab
When swabbing to check for the presence of vi-
rus, a long, highly absorbent swab passed up the 
ventral meatus of the nasal passageways to the 
Figure 3. Typical gross findings in EHV abortion include meconium staining, blood-stained fluid 
pooling in body cavities, enlarged spotty liver and prominent splenic follicles. (Images courtesy of 
Prof Ken Smith, RVC)
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baseline between 60–80 days (Thomson 
et al, 1976). Measured by complement 
fixation (CF) test (Doll et al, 1953a; 1953b).
zz IgG:  detectable 8–10 days after infection, 
peaking at 30–40 days, persisting for 
many months (>9 months). Measured by 
virus neutralisation (VN) or ELISA (the 
latter claimed to be able to differentiate 
between EHV-1 and EHV-4).
zz Technique: take a baseline sample 
and repeat sample 10–14 days later 
(Thompson et al, 1976). Significant 
increase in CF (IgM) antibody level is 
usually defined as a four-fold or greater 
increase in titre, but can be stimulated by 
vaccination as well as infection.
zz Interpretation: a high CF titre (IgM) 
in a single serum sample from a 
non-vaccinated horse provides good 
preliminary evidence of EHV-1 infection 
and is a valuable initial diagnostic test in 
suspected EHM cases.
zz Note: previous vaccination and maternal 
antibodies confound the interpretation 
of serological investigations, particularly 
in bloodstock and foals.
zz Haematology may be used to indicate the 
presence of infection; however, results 
are non-specific and difficult to interpret 
if only a single sample is taken. For the 
first 7–10  days after infection a transient 
leucopenia with lymphopenia is expected. 
Leucopenia is replaced by a leucocytosis 
with lymphocytosis up to 21  days after 
infection. In neonatal foals, a lymphocyte 
count of <2x109/l is associated with a 
very poor prognosis and a strong clinical 
suspicion of neonatal EHV-1 infection 
(Perkins et al, 1999).
Tissue: e.g. fetal, placental or central nervous 
system (CNS) tissue (Smith et al, 2004)
zz Histopathological examination of EHV-1 
infected tissues typically reveals eosinophilic 
inclusion bodies, vasculitis and often 
thrombosis of CNS blood vessels (Whitwell 
et al 1992a; 1992b)
zz Immunohistochemistry of fetal or placental 
tissues may be used to identify EHV-1 
antigen.
Cerebrospinal fluid (CSF) in EHM cases
zz Xanthochromic (yellow coloured) CSF — 
see Figure 4)
zz Total protein is typically increased without 
a concomitant increase in leucocytes
zz Concurrent xanthochromia and elevated 
protein is highly suggestive, but not 
Table 4. History and samples to collect in the face of suspected 
EHV-1 abortion, weak neonatal foal or EHM
Observation / 
Samples
Details/reasons/actions  Tests requested
History Abortion >5 months gestation
Sometimes a rapid delivery with the foetus 
being expelled still contained within the 
placenta (“red bag”)
EHV-1 vaccination history (if known)
Absence of any other gross findings is 
suggestive however other conditions can 
occur concurrently with EHV
Fetal and placental tis-
sue for PCR screening and 
histopathology
Weak neonatal 
foal
Anti-coagulated blood Haematology
(not specific for EHV)
Gross fetal 
pathology
Fresh fetus (limited autolysis)
Meconium staining
Gross pathology 
of fetal organs
Copious, blood stained fluid in body 
cavities
Pulmonary oedema
Enlarged spotty liver
Prominent splenic follicles
Fetal liver, lung, 
thymus (two 
pooled samples)
Place in one pot of neutral buffered formal 
saline to detect viral antigen
Place in a second pot of virus transport 
medium for virus isolation (AHT labs)
Immunohistochemistry 
Virus isolation
Deep nasopharyn-
geal swab
To detect viral DNA/infectious virus 
Place in viral transport medium with antibi-
otics (e.g. white top tube from AHT)
 Refrigerate sample (4 °C)
Transport to laboratory urgently
Quantitative PCR*
Virus isolation
Single blood 
sample
Anti-coagulated (EDTA or LiHep)
To detect viral DNA in white blood cells 
(buffy coat)
*Quantitative PCR
Virus isolation
Paired blood 
samples
Clotted for antibody tests
At an interval of 10–14 days
— recent infection indicated with fourfold 
or greater rise in antibody titre in absence 
of recent vaccination 
-— not diagnostic for EHV abortion
-— moderate to high antibody titres may be 
found in EHM cases in absence of recent 
vaccination 
*Complement fixation test
Cerebrospinal fluid 
(suspected EHM 
only)
Assess colour: xanthochromic (yellow 
discolouration)
Indirect measures of EHV-1 infection.
Blood contamination during sampling may 
make interpretation difficult
Total protein
White blood cell count
Virus-specific antibodies
Figure 4. Normal (above) and xanthochromic 
(yellow, below) cerebrospinal fluid.
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diagnostic, of EHM in horses with 
supportive clinical signs
zz Antibodies to EHV-1 in the CSF may be 
from leakage as a result of vasculitis, not 
from local production, so this does not 
definitively confirm EHM and may be the 
result of EHV-1 exposure.
EHV-1 prevention resources
Good resources to act as guides for the control 
of EHV-1 include the HBLB codes of practice 
https://codes.hblb.org.uk/index.php/page/32; 
and Equibiosafe App https://itunes.apple.com/
gb/app/equibiosafe/id1131137694), which is 
provided free to horse trainers, owners, breed-
ers and veterinary surgeons in the UK by the 
Horserace Betting Levy Board and the National 
Trainers Federation, and the AAEP/USDA guide 
in USA https://aaep.org/guidelines/infectious-
disease-control/equine-herpesvirus-resources.
Steps to prevent EHV-1 
abortion or manage an 
abortion outbreak 
The following steps are in accordance with the 
HBLB Codes of Practice (https://codes.hblb.
org.uk/index.php/page/32)
Prevention of disease entry to premises
Transmission of EHV-1 onto a property cannot 
be prevented, because the majority of horses 
carry latent (and thus undetectable) EHV-1 
that may reactivate unpredictably, often follow-
ing unknown stress events. To reduce the risk 
of disease entry:
zz New arrivals should ideally have been 
vaccinated in advance of relocation to their 
new premises, and should be kept isolated 
from other horses until sufficient time 
(usually 3 weeks) has passed for disease to 
become apparent. 
zz On studs, newly arrived and ‘walk-in’ 
mares should be separated from resident 
in-foal mares. Mares arriving at studs to 
foal should be transported at least 28 days 
before the foaling due date. 
zz Horses that have arrived from sales or 
markets are high-risk and should be subject 
to more stringent isolation and biosecurity 
measures. 
zz Young stock (less than 2  years old) are 
a major source of EHV-1 so should be 
separated from pregnant mares at all times. 
zz In yards with no pregnant mares, an 
isolation period of at least 21  days is 
advised, because viral shedding may occur 
after reactivation of the virus induced by 
the stress of moving. 
zz Minimising stress in resident horses, 
including transport, disruption of established 
social groups, and tapered weaning 
should assist in reducing the frequency of 
reactivation of the virus from the latent state.
Limiting the spread and severity 
of disease
Different age groups should not be mixed.
zz Group size should be kept as small as 
practicable
zz Pregnant mares should be separated from 
other horses and kept in small groups to 
minimise the risk of a large-scale outbreak
zz Mares in their last trimester should ideally 
be housed and managed individually
zz Isolation areas should be geographically 
separate and biosecurity rigorously 
maintained.
In the event of a suspect case
If a suspect case occurs the horse should be 
isolated immediately and appropriate samples 
taken. Isolation can be in a remote area of the 
existing premises or even some miles distant 
from these premises, if there is safe place for 
this to happen.
zz Collect appropriate samples. The intact fetus 
and placenta should ideally be transported 
to a laboratory. If this is not possible 
then fresh liver, lung, thymus, spleen and 
multiple sites of the chorioallantois should 
be sent and kept cool in transit. In addition, 
samples of the same tissues plus kidney and 
adrenal gland fixed in formalin should be 
sent for histology. Swabs for culture of liver, 
lung, gastric contents, and the cervical pole 
of the chorioallantois may aid the diagnosis 
of causes other than EHV.
zz Make telephone contact with a recognised 
laboratory to provide a comprehensive 
history and information on the premises, 
or ensure this is well documented with the 
submission forms.
zz Photographic recording of an in-field 
abortion may help the pathologist reach 
a diagnosis, particularly if the clinician is 
not experienced in recording their findings 
and recognising abnormal features in an 
aborted fetus or placenta.
zz Appropriate sampling kit including plain and 
formal saline pots, swabs etc. — see Box 1. 
Abortion Kit List — should be available
zz Packaging appropriate for the submission 
of diagnostic specimens (compliant with 
Un No. 3373) — see Box 1. Abortion Kit List.
zz Any in-contacts should be isolated, handled 
either by dedicated personnel or last thing 
in the day, and monitored for clinical signs. 
Rectal temperatures should be taken twice 
daily. A full body shower and change of 
clothes should be undertaken by any person 
after handling in-contact animals, and 
vehicle movements restricted. 
zz Veterinary surgeons investigating 
potentially infectious cases should ideally 
wear personal protective clothing and 
gloves, which should be thoroughly 
disinfected and bagged on site before 
leaving. Disinfection of areas of the vehicle 
at risk of contamination, e.g. floor mat(s) 
,should be considered. A full body shower 
and change of clothes should be undertaken 
as soon as practically possible assuming it 
can not be done on site.
zz If the in-contact group is large and it is 
practical to do so, it should be subdivided 
further, ideally minimising stress by 
keeping the mares within sight and sound, 
but not direct contact, with each other.
zz EHV-1 can survive for limited periods 
depending on the surface and prevailing 
weather conditions. One report states 
3 weeks in vitro (Dayaram et al, 2017). All 
discharges and abortion products from 
affected horses should be cordoned off, 
then removed and the area disinfected 
with viricidal disinfectant (Tsujimure et al, 
Box 1. Abortion kit list
zz Submission form
zz Post-mortem form
zz Laboratory postage labels (UN 3373)
zz Pot(s) with lid(s) for fresh tissue samples.
zz Pot for fetal stomach contents
zz Pot(s) with lid(s) containing formal saline for 
fixed samples
zz Swabs with transport media for placenta, 
liver and/or lung
zz Blood tube(s) for serological screening (first 
of two paired samples) .
zz Packaging materials compliant with UN No. 
3373: 
zz Hard protective outer package
zz Absorbent material (to soak up any 
spillage and provide padding)
zz Inner waterproof packaging (bag) to 
prevent spillage if pots break/leak
zz Packing tape
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2015) e.g. VirkonTM. Bedding should be 
removed and ideally incinerated or bagged 
and disposed of.
zz Disinfect water troughs or cover water 
troughs in places where infected mares are 
resident, to avoid cross-contamination.
zz Stop all movements on and off the premises.
zz Isolate aborted mares for 28 days and do not 
mix with pregnant mares for 56 days, unless 
active laboratory surveillance allows this 
time frame to be shortened.
Limiting the spread to other properties
zz Ensure there is effective communication 
between attending vets, premises’ owners 
and other parties working with the affected 
premises — farriers, dentists etc.
zz Warn of risks of disease transmission 
with personnel and fomites — easy 
and clear biosecurity measures should 
be implemented. https://www.bef.
co.uk/Detail.aspx?page=Horse-Health-
Biosecurity
zz Consider vaccinating horses in the region, 
but separate to the yard and not in-contact.
Vaccination to prevent EHV abortion 
Vaccination of all horses on the yard is indi-
cated to reduce viral shedding. There are two 
groups to consider:
Pregnant mares: vaccinate at 5, 7 and 9 
months of pregnancy. Batching mares together 
for vaccination, by vaccinating within 2 weeks 
either side of optimal date, is considered by the 
group to be acceptable.
Other horses on the breeding premises 
(stallions, non-pregnant mares, youngstock): 
Primary course of V1 and V2 4 weeks apart fol-
lowed by 6-monthly booster vaccination. 
There is evidence that administering influ-
enza and EHV-1 vaccination (using a vaccine 
not currently marketed) on the same day does 
not adversely affect the efficacy of either vac-
cine (Heldens et al, 2001).
Steps to take to prevent EHM 
or respiratory disease
The key to preventing respiratory or neuro-
logical disease from EHV is understanding la-
tency of the virus. It is likely that the majority 
of horses contain latent EHV-1 within white 
blood cells and the trigeminal ganglion. Stress 
may trigger reactivation of latent virus, but 
stress is poorly defined and will be different for 
different horses (Figure 5). For example, taking 
one mare out of a group of pregnant mares will 
mean the remaining mares will likely re-estab-
lish their hierarchy or ‘pecking-order’, leading 
to stress and possible EHV-1 reactivation. 
Vaccination has little impact on EHV-1 la-
tency and reactivation. Due to widespread la-
tency, EHV-1 disease can only be managed and 
not eradicated. EHV-1 (represented by ‘Agent’ 
in Figure 6) can therefore be thought of as be-
ing in equilibrium with the horse (represented 
by ‘Host’ in Figure 3), with the environment 
and in particular management interventions 
acting as a pivot point that favours either the 
agent or the host. Management interventions 
such as adopting the HBLB Code of Practice, 
maintaining small groups, applying good bios-
ecurity, quarantine, regular vaccination, rapid 
diagnoses and restricting movements, all bene-
fit the horse population and reduce the risk and 
impact of EHV-1 infection. These measures do 
not eliminate this risk, hence EHV-1 related 
disease still occurs even in the very best man-
aged systems. However, by not following these 
practices the risk of EHV-1 related disease with 
more extensive and severe outcomes increases. 
Figure 6. Factors favouring the host or the agent in EHV-1 infection.
Figure 5. EHV-1 persists in the host and thus disseminates between the equine generations by 
establishing viral latency and subsequent reactivation (courtesy of Prof George Allen, Gluck Equine 
Research Centre).
Horses latently infected with EHV-1 or EHV-4
Infection of young horses
Nasal shedding of 
infectious virus
Recruitment of new 
hosts into cycle
Reactivation of virus 
from latency
Establishment of viral 
from latency
Agent Host
Environment
Management  
interventions
Favouring EHV-1:
zz Not adopting HBLB Code of 
Practice
zz Mixing age groups
zz Poor biosecurity
zz No vaccination
zz No quarantine
zz No disease diagnosis
zz No movement restrictions
Favouring horses:
zz Adopting HBLB Code of 
Practice
zz Small groups
zz Good biosecurity
zz Regular vaccination
zz Using quarantine
zz Rapid diagnosis
zz Restricting movement
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Management and treatment of 
horses infected with EHV-1
It is not feasible to prevent introduction of 
EHV-1 or 4 onto a premises, therefore there is 
no point ‘blacklisting’ animals with previously 
confirmed infection. All new horses should be 
managed under the assumption that they are 
potentially incubating or actively shedding 
or may reactivate latent EHV-1 or -4 shortly 
after arrival. Thus, a quarantine period of at 
least 3 weeks, with daily monitoring of rectal 
temperature, is advised. If quarantine facilities 
are limited, then discussion with the owner in 
advance of new arrivals can help to identify 
and facilitate temporary but effective arrange-
ments, including staff training. 
Management and treatment of horses 
with EHM
The following interventions may help in the man-
agement of EHM (Pusterla and Hussey, 2014):
zz Provide adequate bedding and bandaging 
to prevent trauma particularly to the lower 
limbs and head
zz Maintain a quiet environment to prevent 
excitement
zz Consider the use of slings (e.g. Anderson 
sling) for recumbent horses, although the 
prognosis in such cases is poor
zz Place in-dwelling Foley catheter in horses 
with bladder paralysis, urinary retention 
and overflow incontinence
zz Apply petroleum jelly around the perineum 
along with an extension line to direct urine 
away and prevent scalding
zz Cystitis is a common complication and 
antimicrobial therapy is often indicated
zz Evacuate faeces regularly if there is faecal 
incontinence/rectal impaction, to prevent 
rectal tears 
zz Provide intravenous or enteral fluids 
as necessary.
The following medications may also be 
used,  although their justification is theoretical, 
as no studies have been performed to demon-
strate efficacy in EHM: 
zz Non-steroidal anti-inflammatory drugs are 
used commonly as adjunctive therapy, although 
their capacity to affect the development of the 
lesions of EHM is unknown (e.g. flunixin 
1 mg/kg IV or PO BID).
zz Corticosteroids could aid in the control or 
prevention of the cellular response adjacent 
to infection of the CNS endothelial cells, 
thereby potentially reducing vasculitis, 
thrombosis and resultant neural injury. 
pregnant mares (Mumford et al, 1987)
zz Reports of concurrent outbreaks of abortion 
and neurological disease (Charlton et al, 
1976; McCartan et al, 1995).
Less commonly there have been reports in 
vaccinated animals, for example in one out-
break of 61 clinically affected horses, 6/7 preg-
nant mares aborted and 8 horses developed 
EHM (Walter et al, 2013).
EHV-1 and 4 vaccination can lead to a re-
duction in infectious virus circulating in the 
population and has likely contributed, along-
side the managemental preventative practices 
adopted over this time, to fewer outbreaks of 
disease being reported. There is also evidence of 
reduced respiratory disease and nasopharyngeal 
virus shedding and abortion in vaccinated ani-
mals (Heldens et al, 2001; Goodman et al, 2006). 
However, in vaccinated pregnant mares, cases of 
abortion still occur and vaccination is only one 
tool in the prevention of abortive disease. 
In contrast, the efficacy of vaccination to pre-
vent the development of EHM is unknown. The 
pathogenesis of EHM is poorly characterised, 
but it has been postulated that immune-medi-
ated disease involving immune complexes plays 
some role (Edington et al, 1986). In addition, the 
case for vaccination is complicated by reports of 
increased risk of EHM: when horses had been 
vaccinated against EHV-1 in the preceding year 
(Henninger et al, 2007); and approximately 
5 weeks before the outbreak (Traub-Dargatz et 
al, 2013). These findings may indirectly support 
the theory of immune-mediated involvement in 
the pathogenesis of EHM. Older horses (>15yrs 
old) are known to be at greater risk of EHM 
(Allen et al, 2008). When age was considered, 
recent vaccination ceased to be a risk factor in 
the Henninger et al (2007) study. The role of 
vaccination as a risk factor for EHM therefore 
remains uncertain. The current vaccines do not 
claim to protect against EHM and should only 
be offered as a means of reducing nasal shed-
ding of virus from healthy horses and thus re-
ducing environmental load of EHV-1 and -4. 
Vaccinating horses in the face of an out-
break of EHM is contraindicated, for the above 
reasons, and also interferes with potential se-
rological screening of in-contacts. That said, 
vaccination may be advisable for the horses 
outside the immediate geographical location of 
the outbreak, to reduce the long-term EHV-1 
shedding and improve herd immunity — the 
increased owner awareness of EHV that ac-
companies these outbreaks may be used to en-
courage this. 
However, they may also have a potentially 
deleterious immunospressive effect. 
Therefore reserving their use to recumbent 
cases or severe ataxia in which the 
prognosis is guarded for survival is sensible 
(Lunn et al, 2009) (e.g. sodium phosphate 
dexamethasone 0.1mg/kg IV SID). 
zz Nucleoside analogues (Garre et al 2007a; 
2007b). 
zz Acyclovir 10 mg/kg PO five times 
daily. Note  poor bioavailability and 
questionable efficacy with EHV-1.
zz Valacyclovir 20–40 mg/kg PO TID.
Better bioavailability than acyclovir 
but more expensive (Garre et al, 2009a; 
2009b; Maxwell et al, 2009; 2017). It 
potentially reduces severity of EHM 
if administered 2  days after challenge 
infection at onset of fever.
zz Ganciclovir 2.5 mg/kg intravenously 
q8hours for first 24 hours then orally 
every 12 hours. In vitro this is the most 
potent drug in the class, but it is very 
expensive (Carmichael et al, 2013).
zz Low molecular weight heparin may reduce 
thrombosis: 80 U/kg q24 hours (Walter et al, 
2016; Stokol et al, 2018).
zz Immunostimulants such as Parapoxovis 
in one study of natural EHV-1 exposure 
caused a reduction in clinical signs of 
respiratory disease (Ons et al, 2014). Their 
use has not been evaluated in the context 
of EHM outbreaks and it is not licensed for 
this purpose. Therefore the authors do not 
recommend this for the use in EHM cases.
zz Aspirin has a theoretical indication for the 
prevention or propagation of thrombus 
formation — 5–20 mg/kg PO q12–48 hours.
If ataxia is detected, the horse should be 
walked in a figure-of-eight twice daily to moni-
tor recovery or progression of clinical signs. 
Some horses will show no noticeable premoni-
tory signs, such as pyrexia, but present im-
mediately with EHM. Severely EHM-affected 
horses may recover, but most are euthanased 
within 48 hours on welfare grounds due to sec-
ondary complications, for example bacterial 
pneumonia, bacterial cystitis and/or myopathy.
EHV-1 vaccination:  
when and why?
Epidemics of herpesvirus respiratory disease, 
abortion and /or paralysis were relatively com-
mon in the 1960s, 1970s and 80s, for example:
zz Outbreaks in which abortions occurred 
in up to 70% of exposed unvaccinated 
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EHV-1 and EHV-4 vaccination in 
competition horses
There are currently no official requirements for 
vaccination against EHV-1 in the United King-
dom. In France, racing Thoroughbreds have 
to receive a primary course of three vaccina-
tions followed by annual boosters, in line with 
their requirements for equine influenza. This 
is in conflict with the manufacturer’s recom-
mendations and current evidence. For effective 
protection, antibody titres are likely to require 
boosting at 6-month intervals. Therefore, hors-
es should be vaccinated every 6 months in line 
with datasheet recommendations. 
In Thoroughbred racing in the UK, vac-
cination against EHV-1 is not uncommon to 
protect against respiratory disease and the 
associated lower airway inflammation. Some 
trainers also believe that vaccination can act 
as a general immunostimulant; this may be 
related to the non-specific effects of adjuvant 
within the vaccine formulation, although 
there is currently no scientific evidence to sup-
port this concept. 
In other affiliated sport horse disciplines 
there is limited EHV-1 vaccination uptake. 
Postulated reasons are cost, little to no recog-
nition of the risks posed by EHV-1 infection, 
lack of compulsory vaccination by regulatory 
bodies and a reluctance to engage with the sub-
ject. In contrast, there are robust arguments in 
favour of EHV-1 vaccination amongst these 
elite athletic horses, many of which travel na-
tionally and internationally on a regular basis, 
mixing with other horses from many different 
countries. Such arguments including protec-
tion against respiratory disease and thus loss of 
work and performance, as well as contribution 
to protection of the national equine herd. Im-
proved methods and efforts to communicate 
this message are required. The development of 
a bivalent vaccine incorporating influenza vi-
rus and EHV-1 may facilitate uptake by horse-
owners and thus improve protection nationally 
(Gildea et al, 2016). 
It is recommended that the following groups 
of horses be re-vaccinated against EHV-1 at 
6-month intervals:
zz Horses less than 5 years of age (but 
>6 months old)
zz Horses that may come into contact with 
pregnant mares
zz Horses housed at facilities with frequent 
equine movements on and off the premises
zz Performance or show horses in high-risk 
areas where horses mingle in close 
proximity, for example racetracks or 
show jumping, eventing and dressage 
competitions. 
Vaccination should be at suitable time 
points in the horses’ competition schedules, to 
avoid any impact of vaccine reactions, to allow 
enough time to comply with requirements of 
different organisations and to allow enough 
time (>7  days) for an immune response to 
be generated. In the authors’ opinion, horses 
should be rested for 2–3 days after vaccination.
 
Future directions in controlling 
EHV-1
Evidence suggests improved protection against 
EHV‐1 will likely require both neutralising an-
tibody and cell-mediated cytotoxic T-lympho-
cyte (CTL) responses. Mucosal antibodies can 
play a role in preventing infection of the res-
piratory tract and in limiting virus shedding. 
Cytotoxic lymphocytes that lyse virus‐infected 
cells appear to be required to prevent abortion. 
Control of cell‐associated viremia is thought to 
be critical for the prevention of EHV‐1 abor-
tion and, presumably, neurological disease. Se-
rum antibody titres correlate with virus shed-
ding rather than the duration of cell‐associated 
viremia or the outcome of pregnancy following 
challenge infection (Kydd et al, 2006).
Vaccine technologies
Killed vaccines
Chemically inactivated virus can be whole or 
split using detergents, for example Equip EHV1,4 
(Zoetis). Commercial preparations include an 
adjuvant to increase the amplitude of the im-
mune response (e.g. aluminium hydroxide, or 
carbomer). It is thought to require both EHV-1 
and -4 antigens to cross-protect. Vaccines can 
stimulate both virus neutralising and comple-
ment fixation antibodies, the levels of which have 
been linked to the reduction of virus shedding. 
Some of these vaccines have a licensed claim for 
reduction in abortion but there is no licence for 
protection against neurological disease.
Vectored vaccines
These are constructed by inserting genes of 
interest into live viruses such as poxviruses, 
adenoviruses or herpesviruses that are used as 
a vaccine delivery tool, e.g. Canarypox virus 
(Merial) (Minke et al, 2006) or modified Vac-
cinia virus Ankara (non-replicating chicken 
adapted) (Huemer et al, 2000), that can by-
pass maternal antibodies. These are cheap to 
produce once established. These allow sim-
ple DIVA strategies (differentiating infected 
from vaccinated animals). The identity of 
the immunodominant protective antigens of 
EHV-1 to insert into the genome has not yet 
been determined for all equine genotypes.
Subunit vaccines
These contain one or more pure or semi-pure 
antigens. They are safe to use, but are expensive 
to produce commercially. The immunodomi-
nant protective antigens of EHV-1 have yet to 
be identified for use in subunit vaccines.
Live attenuated vaccines
Historically these are based on highly passaged 
virus isolates that have lost their virulence yet 
still induce an immune response, e.g. Rhino-
mune (RacH strain). They closely mimic natu-
ral infection with the full ‘antigenic breadth’ 
Modern molecular biology techniques allow 
rational attenuation by specific modification 
of the virus genome. Live attenuated vaccines 
against a number of different infectious diseas-
es are known to stimulate both antibody and T-
lymphocyte responses in a number of different 
animal species. For safety, the vaccine must be 
incapable of reverting to a more virulent form. 
These do provide the opportunity for DIVA.
Conclusions
Understanding the biology of EHV-1 and -4 
helps to construct strategies to reduce the inci-
dence of disease, and central to this should be 
the recommendation to vaccinate at herd level. 
Ideally all horses on a yard would be vaccinated, 
with coverage reaching 70% of the national herd. 
Vaccination decreases the amount and duration 
of nasopharyngeal shedding of the virus, and 
therefore environmental contagion. Yard vacci-
nation in the face of an outbreak is contraindi-
cated, as the state of infection/immune response 
of the individuals will be unknown. Vaccination 
of closely associated horses (e.g. geographi-
cally), but on separate premises to the original 
outbreak, is potentially beneficial and should be 
judged on an individual basis in consultation 
with the testing laboratory and/or epidemio-
logical input. Vaccination remains a valuable 
tool used appropriately to reduce environmental 
contagion and reduce disease incidence, when 
integrated into strict biosecurity and hygiene 
measures; however, currently the lack of a vac-
cine stimulating an antibody response that can 
be differentiated from natural infection (DIVA 
vaccine) makes it difficult to screen horses sero-
logically once they have been vaccinated.
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Upper airway disease can be a major cause of poor performance and adventitious respiratory noises in the equine athlete. Owners, trainers and clinicians will often have anecdotal ways of diagnosing upper airway conditions that, in many cases, may be unreliable and misleading. Recent advances in their diagnosis using exercising endoscopy and diagnostic imaging have allowed more detailed and precise identification of most causes of upper airway obstruction. With more accurate diagnoses, surgical and conservative treatments can be selected much more confidently, potentially resulting in a more successful outcome. 
History
As with any clinical investigation an accurate history from the owner, trainer, rider or jockey of any horse is crucial. Poor per-formance and noise production are the two usual reasons why an upper airway examination is requested, and investigation of the former is generally less rewarding compared with the latter (Allen and Franklin, 2010). Ascertaining what the report of ‘poor perfor-mance’ actually entails is also important. This can range from the horse breathing heavily in a dressage test to collapsing half way through a race. 
Finding out the characteristics of any noise the horse makes is also beneficial. Although never proven to be consistently reli-able, the characteristics of the noise may suggest the presence of particular conditions. For example, ‘whistling’ is more often anecdotally associated with cases of recurrent laryngeal neuropa-thy (RLN), vocal fold collapse (VFC) or medial deviation of the aryepiglottic folds (MDAF); ‘gurgling’ is often associated with forms of palatal dysfunction. 
General clinical examination 
Auscultation of the lungs and heart is particularly useful in help-ing eliminate any lower respiratory tract or cardiac conditions that may be the cause of the clinical signs being investigated. Palpation of the laryngeal structures, through the skin, can provide useful diagnostic information. For example, in cases of RLN, atrophy of the cricoarytenoideus dorsalis (CAD) muscle allows palpation of the muscular process of the arytenoid cartilage, and there is often an obvious asymmetry from left to right. However, if the clinician is less experienced in performing this examination, then it can be un-reliable. Asymmetric morphology of the larynx may also indicate the presence of congenital defects, such as a fourth branchial arch defect (4-BAD). Close examination and palpation around the lat-eral and ventral aspect of the pharyngeal and laryngeal region may also reveal evidence of scars from previous upper airway surgeries. 
Sound analysis 
‘Wind testing’ of horses, both as part of the clinical examination of suspected upper airway conditions and during pre-purchase examination, is invaluable. Listening to the patient while it is exer-cising is often one of the first diagnostic steps to undertake, either with the horse ridden or lunged. When examined on the lunge ideally the horse needs to be cantering to ensure that its respira-tory rate is synchronised to one breath for each stride. Inspira-tion will take place in the flight phase (as the head is raised) and expiration when the front limbs strike the ground (with the head lowered), thus allowing easier differentiation of the timing of any adventitious noise in the respiratory cycle. If noise is only report-ed with the horse exercising maximally, then the horse should be wind tested working at the same intensity. Equally, if the reports 
Diagnosing upper airway 
disorders
The correct diagnosis of upper airway conditions in the horses is imperative to ensure that the horse receives the correct and most appropriate treatment and management. With the introduction of overground exercising endoscopy, examination of the patient is now readily available. Ultrasonography of the upper airway has also entered into the diagnostic repertoire of the clinician. However, interpretation of these examinations is not always straightforward with some conditions, most notably dorsal displacement of the soft palate, still sometimes questionably elusive. Additionally, many horses are found to have multiple forms of upper airway obstruction, so a complete diagnosis is essential to ensure that some conditions are not overlooked. 10.12968/ukve.2018.2.3.84
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Keeping up with developments 
Pathogenesis of equine 
squamous and glandular 
gastric disease
The pathogenesis of ESGD is 
different from that of EGGD; 
treatment and approaches to 
prevention therefore differ
Managing the chronic 
grass sickness case 
Correctly identifying chronic (mild) 
cases is important as these can 
survive with intensive nursing care
Diagnosing upper airway 
disorders
Exercising endoscopic examination 
is useful in the diagnosis of upper 
airway conditions
Suspensory branch injuries 
in sports horses and 
racehorses
There are many manifestations 
of suspensory ligament branch 
injuries but a lack of evidence  
on effective treatment
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